Chronic myelogenous leukemia: A review and update of therapeutic strategies

Guillermo Garcia-Manero, Stefan Faderl, Susan O'Brien, Jorge Cortes, Moshe Talpaz, Hagop M. Kantarjian

Research output: Contribution to journalReview article

65 Scopus citations

Abstract

The prognosis of patients with chronic myelogenous leukemia (CML) has significantly improved over the last 20 years. Whereas the median survival durations were 4-5 years in the era of hydroxyurea therapy, the introduction of interferon-a, both alone and in combination with cytosine arabinoside, has nearly doubled these numbers. However, the development of imatinib, a BCR-ABL selective tyrosine kinase inhibitor, represents one of the biggest leaps forward in the treatment of CML and will probably have a significant impact on the course and potential one of CML. Here, we review the biology of CML, its clinical features, and therapeutic options in this disease.

Original languageEnglish (US)
Pages (from-to)437-457
Number of pages21
JournalCancer
Volume98
Issue number3
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Chronic myelogenous leukemia: A review and update of therapeutic strategies'. Together they form a unique fingerprint.

  • Cite this

    Garcia-Manero, G., Faderl, S., O'Brien, S., Cortes, J., Talpaz, M., & Kantarjian, H. M. (2003). Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer, 98(3), 437-457. https://doi.org/10.1002/cncr.11520